Treating Keratoconus – First North American Centre Using CXL

cr3We are very pleased to be the first centre in North America to offer the revolutionary procedure of Corneal Collagen Crosslinking (CXL) to arrest the progression of keratoconus.

The procedure originated in Europe over 10 year ago. When the clinical results appeared excellent in the scientific literature we acquired all the equipment from Europe and started performing the procedure in January of 2008.

Keratoconus is a degenerative disease of the cornea that comes on in adolescence and tends to progress until patients are in their 40s or 50s. 20% of keratoconus patients in the past required a corneal transplant. With early identification of the disease and treatment this promises to greatly reduce or eliminate the need for a transplant. Of the more then 350 eyes treated to date at the Bochner Eye Institute the patients have ranged from 11 to 55 years of age.

Although the goal of CXL is to arrest the progression of the disease, corneal flattening occurs in a high percentage of patients by 6 months with further improvement at 1 year. In addition to the treatment of keratoconus the CXL procedure can be used to stabilize the vision following radial keratototmy. We are accepting referrals for CXL from patients throughout North America. In addition to patients from across Canada we have treated patients from New York, Pennsylvania, Texas, and California.

To learn more about keratoconus and this leading-edge treatment, please contact Dr. Raymond Stein and the team at Bochner Eye Institute at 416-960-2020, or by using the contact form below.

Enter this code in the field below
Enter this code in the field below

Tags: , ,